3,690
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Approaching drug-induced parkinsonism from a neurohospitalist perspective

Pages 93-95 | Received 17 Nov 2018, Accepted 10 Jan 2019, Published online: 16 Jan 2019

References

  • Lee PH, Yeo SH, Yong SW, et al. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2007;78(11):1250–1252.
  • Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76:779–787.
  • Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord. 2008;23:401–404.
  • Shuaib UA, Rajput AH, Robinson CA, et al. Neuroleptic-induced Parkinsonism: clinicopathological study. Mov Disord. 2016;31:360–365.
  • Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226–2231.
  • Blanchet PJ, Kivenko V. Drug-induced parkinsonism: diagnosis and management. J Parkinsonism Restless Legs Syndr. 2016;6:83–91.
  • Kim JS, Youn J, Shin H, et al. Nonmotor symptoms in drug-induced parkinsonism and drug-naïve parkinson disease. Can J Neuro Sci. 2013;40:36–41.
  • Morley JF, Pawlowski SM, Kesari A, et al. Motor and non-motor features of Parkinson’s disease that predict persistent drug-induced parkinsonism. Parkinsonism Relat Disord. 2014;20(7):738–742.
  • Morley JF, Cheng G, Dubroff JG, et al. Olfactory impairment predicts underlying dopaminergic deficit in presumed drug-induced parkinsonism. Mov Disord Clin Pract. 2016;4:603–606.
  • Howel MJ. Parasomnias: an updated review. Neurotherapeutics. 2012;9:753–775.
  • Ravn AH, Thyseen JP, Egeberg A. Skin disorders in Parkinson’s disease: potential biomarkers and risk factors. Clin Cosmet Invetig Dermatol. 2017;10:87–92.
  • Fereshtehnejad SM, Zeighami Y, Dagher A, et al. Clinical criteria for subtyping Parkinson’s disease: biomarker and longitudinal progression. Brain. 2017;140:1959–1976.
  • Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci. 1990;2:64–66.
  • Alvarez MVG, Evidente VGH. Understanding drug-induced parkinsonism separating pearls from oy-sters. Neurology. 2008;70:e32–e34.
  • Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42.
  • Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8:15–21.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.